1. Introduction {#sec1}
===============

β-Amyloid (Aβ) accumulation is believed to be the initial pathology of the most common type of neurological disease leading to dementia, Alzheimer\'s disease (AD) [@bib1]. Abnormal levels of Aβ are associated with longitudinal cognitive decline in healthy elderly [@bib2] and progression to AD dementia in subjects with mild cognitive impairment (MCI) [@bib3]. A verified Aβ status can be used to improve the accuracy of AD diagnostics and for including participants in trials of novel AD drugs, as currently used in several clinical trials [@bib4]. Given the devastating symptoms of AD, the high number of affected people, and the tremendous costs for society (US\$ 259 billion per year for dementia in the US alone), there will be a great pressure on the health care system to identify persons with abnormal Aβ deposition when disease-modifying AD treatments become available [@bib5].

Brain Aβ can be detected *in vivo* either by performing a lumbar puncture (LP) and analyzing the levels of the peptide Aβ~42~ in cerebrospinal fluid (CSF) or by performing a positron emission tomography (PET) scan using a ligand that binds to Aβ fibrils (Aβ PET). There are no significant differences between the two methods in terms of accuracy for identifying AD [@bib6], [@bib7], and they are used mostly not only in research but also in clinical practice at some specialized memory clinics. However, because these methods are invasive, costly, and not available in all health care settings, a screening process to select individuals for LP or PET testing, both in clinical practice and clinical treatment trials, would be very useful. Several studies on amyloid prediction tools or blood-based Aβ biomarkers exist, but due to lack of or failed validations, low accuracies, or the usage of advanced technology or extensive neuropsychological testing, none of them are currently being used in clinical or research settings, to the best of our knowledge [@bib8], [@bib9], [@bib10], [@bib11], [@bib12].

In the present study, we aimed to develop algorithms that estimate the risk of being Aβ positive using readily available and noninvasive measures and tests. Nondemented subjects with either subjective or objective cognitive symptoms were examined to provide a clinically relevant target population. The models were developed in a training cohort and validated in an independent population. In a second step, we analyzed the added value of including the plasma biomarkers tau, neurofilament light (NfL), and the Aβ~42~/Aβ~40~ ratio.

2. Materials and methods {#sec2}
========================

2.1. Participants of the training cohort (BioFINDER) {#sec2.1}
----------------------------------------------------

The Swedish BioFINDER study (Biomarkers For Identifying Neurodegenerative Disorders Early and Reliably) is a prospective study that focuses on identifying key mechanisms and improving clinical diagnostics of AD and other neurodegenerative disorders. Details about the Swedish BioFINDER study design have been published previously [@bib12], [@bib13] and are available at <http://biofinder.se>. In the present study, we used the BioFINDER cohort of prospectively and consecutively included nondemented participants with cognitive complaints. They were enrolled between 2010 and 2015, mostly from primary care centers in the Southern part of Sweden. The inclusion/exclusion criteria are provided in the [Supplementary Material](#appsec1){ref-type="sec"}. Based on the result of a comprehensive neuropsychological battery and the clinical assessment of a senior neuropsychologist and two physicians specialized in neurocognitive disorders, 54% of the 391 participants were classified as having MCI and 46% as having subjective cognitive decline [@bib14].

2.2. Amyloid outcome measures in BioFINDER {#sec2.2}
------------------------------------------

Aβ was measured using ^18^F-flutemetamol PET if available (n = 241), otherwise CSF Aβ~42~ was used (n = 150). The scanning [@bib15] and processing [@bib13] procedures have been described previously. The weighted mean standardized uptake value ratio (SUVR) from a global neocortical region of interest [@bib16] relative to a composite reference region (white matter, cerebellum and brainstem [@bib13]) was used to determine the Aβ status. The SUVR cutoff for Aβ positivity was determined using unbiased mixture modeling statistics, which is a well-validated method for determining such a cutoff [@bib13], [@bib17], [@bib18]. The resulting cutoff for Aβ positivity was \>0.738 SUVR.

LP and CSF handling followed a structured protocol [@bib15]. CSF levels of Aβ~42~ were analyzed using INNOTEST ELISAs (Fujirebio Europe, Ghent, Belgium). The CSF Aβ~42~ cutoff for Aβ abnormality was determined using the optimized Youden\'s Index against Aβ PET in BioFINDER (CSF Aβ~42~ \< 552 ng/L; sensitivity 93%, specificity 84%).

2.3. Predictor variables of Aβ positivity {#sec2.3}
-----------------------------------------

Different types of predictors were examined in the primary analysis, including demographics (age, education, and sex), apolipoprotein E (*APOE*) genotype, cognitive test scores, and white matter lesions. The cognitive tests were administered by experienced research nurses who were blinded to the Aβ status of the participants.

*APOE* genotypes were analyzed from blood samples, and the participants were stratified according to Aβ risk into the following groups (see reference [@bib19] for rationale): (1) ε2/ε2 or ε2/ε3, (2) ε3/ε3, (3) ε2/ε4 or ε3/ε4, and (4) ε4/ε4. *APOE* ε3/ε3 was the reference category.

Episodic memory function was measured with the delayed recall part of the 10-word list from the Alzheimer\'s Disease Assessment Scale--cognition [@bib20]. Cognitive function was also assessed with the Mini--Mental State Examination (MMSE) [@bib21]. Both the total score and the score from the orientation and memory parts of the test were used. The scores from the orientation and memory parts of the MMSE were used based on previous findings showing that the orientation to time and place and the three-word delayed recall parts can differentiate MCI and dementia due to AD from other causes of cognitive impairment [@bib22], [@bib23]. It consists of orientation to place (country, county/state, city, building/place, and floor), orientation to time (year, season, month, day of the week, and date), and three words that are being recalled after a short distraction task.

We also examined A Quick Test of Cognitive Speed (AQT)---color and form score, which is a sensitive test for attention and executive function to account for non-AD-specific cognitive impairment [@bib24], [@bib25]. AQT was used alone and as a ratio with the delayed word recall test and MMSE orientation and memory.

Magnetic resonance imaging was performed on a 3-Tesla Siemens Tim Trio scanner (Siemens Medical Solutions, Erlangen, Germany). T2 FLAIR images were used for rating white matter lesions according to the ARWMC scale [@bib26] to account for the impact of cerebrovascular pathology on cognitive impairment.

In a secondary analysis, we added the plasma biomarkers tau, the ratio of Aβ~42~/Aβ~40~, and NfL, which previously have been tested as AD biomarkers [@bib27], [@bib28], [@bib29]. Plasma Aβ~42~ and Aβ~40~ levels were determined using the EUROIMMUN ELISAs (EUROIMMUN, Lubeck, Germany). The total levels of Aβ~42~ and Aβ~40~ were used to calculate the Aβ~42~/Aβ~40~ ratio. Plasma tau and NfL concentrations were measured on a Simoa HD-1 analyzer using the Human Total Tau kit (Quanterix, Lexington, MA) for tau and an in-house assay based on the same antibodies and standard protein as in the commercially available NF-light kit (UmanDiagnostics, Umeå, Sweden) for NfL [@bib30]. All predictor variables were available in all patients, except for plasma NfL and tau (n = 346 of 391 participants).

2.4. Validation cohort---Alzheimer\'s Disease Neuroimaging Initiative {#sec2.4}
---------------------------------------------------------------------

A detailed study and data description of the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) as well as inclusion/exclusion criteria and MCI definitions can be found on [www.adni-info.org](http://www.adni-info.org){#intref0030} and in the [Supplementary Material](#appsec1){ref-type="sec"}. Only nondemented subjects with cognitive symptoms were selected, which included participants with early and late MCI and participants from the healthy control cohort who had significant memory concerns.

We included only participants with a complete data set of cognitive test, *APOE*, and Aβ data (Aβ PET or CSF Aβ~42~). This selection resulted in a population of 661 participants, of which 170 had plasma biomarker data.

Aβ status was based on (in order of preference) (1) Aβ PET using the ligand ^18^F-florbetapir, (2) Aβ PET using the ligand ^11^C-Pittsburgh Compound B (PiB), and (3) CSF Aβ~42~ measured using the multiplex xMAP Luminex platform (Luminex Corp, Austin, TX, USA) with the INNO-BIA AlzBio3 kit (Innogenetics, Ghent, Belgium) [@bib31], [@bib32]. Predefined cutoffs for Aβ positivity were used for florbetapir (\>1.11 SUVR) [@bib33], ^11^C-Pittsburgh Compound B (\>1.5 SUVR) [@bib34], and Aβ~42~ (\<192 ng/L) [@bib32]. The methods for these three measures have previously been described [@bib32], [@bib33], [@bib34].

Plasma Aβ~42~ and Aβ~40~ were measured using the INNO-BIA plasma Aβ immunoassay kit (Fujirebio, Ghent, Belgium) on the Luminex 100 immunoassay platform (Luminex Corp) [@bib35]. The total levels of Aβ~42~ and Aβ~40~ were used to calculate the Aβ~42~/Aβ~40~ ratio.

2.5. Statistical analysis {#sec2.5}
-------------------------

Group comparisons were done using the Mann-Whitney *U* test. In [Table 1](#tbl1){ref-type="table"}, we applied Bonferroni correction to adjust for multiple comparisons. *P* values were thus multiplied by 6 and a value of \<0.05 was considered statistically significant. To predict Aβ positivity, the following variables from the training cohort (BioFINDER) were entered in a general linear model: age, gender, presence of APOE ε2/ε2 or ε2/ε3, presence of APOE ε2/ε4 or ε3/ε4, presence of APOE ε4/ε4 (APOE ε3/ε3 was not included because it was the reference variable), total MMSE score, the score from the orientation and delayed recall (memory) parts of the MMSE, the 10-word list delayed recall from Alzheimer\'s Disease Assessment Scale--cognition (number of errors), years of education, AQT score, 10-word list delayed recall/AQT, MMSE orientation and memory/AQT, and degree of white matter lesions (ARWMC score). Using Aβ status as the dependent variable, the general linear model was fitted to the data using the least absolute shrinkage and selection operator (LASSO) [@bib36]. The LASSO analysis uses a type of forward selection logistic regression that provides more robust predictors because it penalizes the absolute value of the coefficients and shrinks irrelevant coefficients to zero. The LASSO was only used for selecting predictor variables in BioFINDER (the training cohort), it could not be directly applied to the ADNI data (validation cohort) because not all BioFINDER variables were present in ADNI (ARWMC and AQT data). To increase the applicability of an Aβ risk model, we also used a reduced set of variables (but the same population) where we excluded the 10-word list delayed recall, AQT, and white matter lesions assessments because these measures are not always available in all settings. In a final step of Aβ risk analyses, we added plasma tau, plasma NfL, and the plasma Aβ~42~/Aβ~40~ ratio to the two LASSO models. The selected variables from the LASSO regression (variables with nonzero estimates) were entered in a logistic regression model to calculate the intercept, the coefficients, and the resulting area under the receiver operating characteristics curve (AUC). The Akaike Information Criterion (AIC) was used to assess the model fit in relation to its complexity (number of variables), where a drop of ≥2 indicated a statistically better model [@bib37]. The best model was considered to be the one with the highest AUC and the lowest AIC. The logistic regression models from BioFINDER were then replicated in different subgroups in BioFINDER and in the independent ADNI cohort for a robust cross-validation. Equations for calculating the individual risk of being Aβ positive were derived from the estimates and intercepts in the different models. The statistics were performed using R, version 3.3 (R Foundation for Statistical Computing, Vienna, Austria, 2013), and SPSS for Mac, version 22 (SPSS Inc., Chicago, IL). The amyloid risk models were implemented online using a R Shiny (version 1.0.0) program.Table 1Characteristics of the training and validation cohortsVariablesBioFINDER (training cohort)ADNI (validation cohort, plasma subset)ADNI (validation cohort, total population)*Aβ−Aβ+TotalAβ−Aβ+TotalAβ−Aβ+Total*N197 (50%)194 (50%)34666 (39%)104 (61%)170311 (47%)350 (53%)661SCD/MCI55%/45%36%/64%^b^46%/54%SMC/EMCI[∗](#tbl1fnlowast){ref-type="table-fn"}/LMCI5%/62%/33%2%/44%/54%^b^3%/51%/46%22%/51%/27%10%/43%/47%^c^15%/47%/38%^i^Age (range)69.8 (60--80)72.1 (60--80)^b^71.0 (60--80)71.0 (56--89)71.9 (57--83)71.5 (56--89)70.4 (7.4)73.4 (6.9)^c^72.2 (55--91)^d^Sex (women)49%43%46%45%44%45%45%46%302 (46%)Education (years)12.1 (3.6)11.4 (3.5)11.8 (3.5)16.4 (2.5)16.2 (2.8)16.3 (2.7)^f^16.4 (2.5)16.4 (2.8)16.2 (2.7)^f^MMSE (0--30 p)28.2 (1.7)27.4 (1.8)^c^27.8 (1.8)28.6 (1.4)27.6 (1.8)^c^28.0 (1.7)28.6 (1.5)27.7 (1.8)^c^28.1 (1.7)^f^MMSE orientation and delayed recall (0--13 p)12.1 (1.0)11.5 (1.4)^c^11.8 (1.2)12.1 (0.9)11.3 (1.5)^c^11.6 (1.3)12.1 (1.1)11.4 (1.5)^c^11.8 (1.4)^g^10-word list delayed recall (0--10 errors)4.1 (2.5)6.0 (2.5)^c^5.0 (2.6)4.3 (2.1)5.9 (2.6)^c^5.2 (2.5)3.8 (2.3)5.5 (2.7)^c^4.7 (2.6)^g^APOE ε2/ε2 or ε2/ε313%2%^c^7%17%2%^c^8%13%3%^c^8%APOE ε3/ε363%29%^c^46%59%28%^c^40%64%33%^c^48%^g^APOE ε2/ε4 or ε3/ε422%50%^c^36%20%55%^c^41%21%51%^c^37%APOE ε4/ε43%19%^c^11%5%16%^a^11%2%13%^c^8%Plasma Aβ~42~/Aβ~40~ ratio0.19 (0.06)0.16 (0.03)^c^0.17 (0.05)0.10 (0.05)0.082 (0.05)^c^0.090 (0.05)^f^Plasma tau (pg/mL)5.3 (2.3)5.5 (2.7)5.40 (2.5)Plasma NfL (pg/mL)24.0 (24)26.7 (17)^c^25.4 (20.9)WML (ARWMC scale, 0--27 p)6.6 (5.7)6.9 (5.4)6.8 (5.6)AQT color-form (seconds)79 (25)85 (29)^a^82 (27)[^2][^3][^4]

3. Results {#sec3}
==========

The characteristics of training (BioFINDER) and validation (ADNI) cohorts are described in the [Supplementary Material](#appsec1){ref-type="sec"} and shown in [Table 1](#tbl1){ref-type="table"}.

3.1. Establishing the amyloid prediction models in BioFINDER {#sec3.1}
------------------------------------------------------------

The different Aβ prediction models are illustrated in [Fig. 1](#fig1){ref-type="fig"}A and [Supplementary Table 1](#appsec1){ref-type="sec"}. The selected variables from the LASSO regression were age, *APOE* ε2ε2/ε2ε3, *APOE* ε2ε4/ε3ε4, *APOE* ε4ε4, and the 10-word list delayed recall (see [Fig. 1](#fig1){ref-type="fig"} legend for a complete list of examined variables). Hereafter, this is referred to as the "delayed recall" model. In a multivariable logistic regression, coefficients and intercept were established ([Supplementary Fig. 1](#appsec1){ref-type="sec"}). The resulting area under the ROC curve (AUC) based on the probabilities from the model was 0.83 (95% CI 0.79--0.87) ([Fig. 1](#fig1){ref-type="fig"}A, [Supplementary Table 1](#appsec1){ref-type="sec"}). Because a 10-word list, grading of white matter lesions, and AQT are not always available in all settings, we also ran another LASSO regression using the same population but removed these three measures. The variables selected by the LASSO regression were then age, *APOE* ε2ε2/ε2ε3, *APOE* ε2ε4/ε3ε4, *APOE* ε4ε4, and MMSE orientation and memory. This is referred to as the "MMSE model." In a logistic regression, this model had slightly less AUC than the delayed recall model (AUC 0.81, 95% CI 0.77--0.85), and a comparison of the AICs also favored the delayed recall model (ΔAIC 17).Fig. 1(A--B) Prediction of Aβ positivity in BioFINDER. Logistic regression analyses of the variables selected in the LASSO analysis. The results are shown as AUCs based on the probabilities from the models. Error bars represent the 95% CI of the AUC, where \>0.5 in the lower bound indicates that the model significantly predicts Aβ positivity. All models were derived from the same 391 subjects. (A) shows the four multivariable amyloid risk models. The colors in (A) correspond to the color coding of the variables in (B) and show the added AUC in addition to the previous variable(s). A vertical dashed line has arbitrarily been added at AUC 0.80 for easier comparison between the models. The delayed recall, MMSE, and plasma models were derived from the different sets of variables (but from the same population) using the LASSO analysis as the selection method. The AIC shows the model fit in relation to its complexity (number of variables) where lower AIC equals a better model fit (a decrease of ≥2 indicates a significantly better model). Detailed data of each cumulative step are shown in [Supplementary Table 1](#appsec1){ref-type="sec"}. (B) shows univariate analyses of the selected variables. Note that the different *APOE* variables show the performance of each specified *APOE* group in contrast to all other groups. The complete performance of *APOE* (divided into 2, 3, and 4 groups, respectively) is shown in [Supplementary Fig. 2](#appsec1){ref-type="sec"}. **Delayed recall model**: Age, 10-word list delayed recall, *APOE* ε2ε2/ε2ε3, ε2ε4/ε3ε4, and ε4ε4. **MMSE model**: As above but with MMSE orientation and memory instead of delayed word recall. **List of predictor variables in the LASSO analysis**: 10-word list delayed recall (from ADAS-cog), MMSE total score (0--30 p), MMSE orientation and memory (0--13 p), AQT (including ratios with the other cognitive measures), white matter lesions (ARWMC scale), presence of *APOE* ε2ε2/ε2ε3, presence of *APOE* ε2ε4/ε3ε4, and presence of *APOE* ε4ε4. In the reduced set of variables (for the MMSE model), white matter lesions, delayed recall, and AQT were excluded (but the same population was used). In the secondary analyses, plasma NfL, plasma Aβ~42~/Aβ~40~ ratio, and plasma tau were added to the two sets of variables (also using the same population). Abbreviations: Aβ, β-amyloid; AIC, Akaike Information Criterion; APOE, apolipoprotein E; ARWMC, age-related white matter changes; AUC, area under the ROC curve; BioFINDER, Biomarkers For Identifying NeuroDegenerative Disorders Early and Reliably; CI, confidence interval; LASSO, least absolute shrinkage and selection operator; MMSE, Mini--Mental State Examination; ROC, receiving operating characteristics.

Next, we reran the aforementioned LASSO analyses but also included the plasma biomarkers Aβ~42~/Aβ~40~, NfL, and tau. The selected variables from the analysis were age, *APOE* ε2ε2/ε2ε3, *APOE* ε2ε4/ε3ε4, *APOE* ε4ε4, the 10-word list delayed recall, and plasma Aβ~42~/Aβ~40~. This produced the best model with ΔAICs of −8 to −34 compared with the other models and the highest AUC of all models (0.85, 95% CI 0.81--0.89) ([Fig. 1](#fig1){ref-type="fig"}A; [Supplementary Table 1](#appsec1){ref-type="sec"}). When excluding grading of white matter lesions, AQT, and 10-word list delayed recall from the LASSO model, plasma Aβ~42~/Aβ~40~ was again selected, in addition to age, *APOE* ε2ε2/ε2ε3, *APOE* ε2ε4/ε3ε4, *APOE* ε4ε4, and MMSE orientation and memory. The AUC from the logistic regression was 0.83 (95% CI 0.79--0.87), which was favorable compared with the MMSE model without plasma Aβ~42~/Aβ~40~ (ΔAUC 0.02 and ΔAIC −16). In univariate analyses of the selected variables from the LASSO regression, plasma Aβ~42~/Aβ~40~ had the highest accuracy (AUC 0.74, 95% CI 0.69--0.79) ([Fig. 1](#fig1){ref-type="fig"}B and [Supplementary Table 1](#appsec1){ref-type="sec"}).

3.2. Replicating the models in ADNI {#sec3.2}
-----------------------------------

The BioFINDER models were replicated in both the ADNI subset where plasma Aβ~42~/Aβ~40~ values were available (n = 170) and in the total eligible ADNI population (n = 661), that is, the equations in [Supplementary Fig. 1](#appsec1){ref-type="sec"} were tested in the ADNI samples (a new model was not fitted in ADNI). The different replications are shown in [Fig. 2](#fig2){ref-type="fig"} and described with exact data in [Supplementary Table 2](#appsec1){ref-type="sec"}. When replicating the delayed recall model in ADNI, the AUC was 0.82 (95% CI 0.75--0.89) compared with 0.83 in BioFINDER. The AUC was 0.83 (95% CI 0.77--0.89) when replicating the delayed recall model *plus* plasma Aβ~42~/Aβ~40~ (AUC 0.85 in BioFINDER). The MMSE model had an AUC of 0.81 (95% CI 0.75--0.88), equal to its original performance in BioFINDER (AUC 0.81, 95% CI 0.77--0.85). Similar performance was seen when adding plasma Aβ~42~/Aβ~40~ (AUC 0.83, 95% CI 0.76--0.89, in ADNI compared with 0.83, 95% CI 0.77--0.85, in BioFINDER). In the total ADNI population (n = 661), both the delayed recall and MMSE models had AUC of 0.80 (95% CI 0.77--0.84 and 0.77--0.83, respectively). The performance of the models in the eight different subpopulations in BioFINDER and ADNI ([Fig. 2](#fig2){ref-type="fig"} and [Supplementary Table 2](#appsec1){ref-type="sec"}) was robust when tested within different age strata or within different groups of cognitive impairment (subjective cognitive decline, early MCI, and late MCI).Fig. 2(A--D) Replication of the amyloid risk models. The top bar in (A--D) shows the model performance in the original total BioFINDER population, and the error bars represent the 95% CI of the AUC. The other bars show the performance when applying the estimates and intercept from the logistic regression analysis on other populations. Vertical dashed lines have been added at AUC 0.80 for easier comparison between the populations. For model description, see [Fig. 1](#fig1){ref-type="fig"} and [Supplementary Fig. 1.](#appsec1){ref-type="sec"} Blue bars represent different BioFINDER populations, and red bars represent different ADNI populations. The age stratification was based on the median age of the population. Abbreviations: ADNI, Alzheimer\'s Disease Neuroimaging Initiative; AUC, area under the ROC curve; BioFINDER, Biomarkers For Identifying NeuroDegenerative Disorders Early and Reliably; CI, confidence interval; EMCI, early MCI; LMCI, late MCI; MCI, mild cognitive impairment; MMSE, Mini--Mental State Examination; ROC, receiving operating characteristics; SCD, subjective cognitive decline; SMC, significant memory concern.

3.3. Calculating the individual risk of being amyloid positive {#sec3.3}
--------------------------------------------------------------

The models were implemented and published on <http://amyloidrisk.com> where the individual probability of being Aβ positive can be calculated, including a 95% CI of the predicted probability. The plasma models were not implemented on the website because we believe further research is needed in terms of assay standardization and preanalytical protocols. ROC curves with sensitivity and specificity for each amyloid risk probability is shown in [Fig. 3](#fig3){ref-type="fig"}A--D. The highest Youden index (sensitivity + specificity − 1) was produced using a cutoff of 56% probability of amyloid positivity for the delayed recall model (sensitivity 71%, specificity 83%), 59% probability for the MMSE model (sensitivity 66%, specificity 83%), 43% for the delayed recall model plus plasma Aβ~42~/Aβ~40~ (sensitivity 85%, specificity 71%), and 50% for the MMSE model plus plasma Aβ~42~/Aβ~40~ (sensitivity 75%, specificity 77%).Fig. 3(A--D) ROC curves of the amyloid risk models. (A-D) show the ROC curves from the four different models. Along the ROC curves, the probability of being amyloid positive (as generated on <http://amyloidrisk.com>) has been denoted and color coded according to the scale on the right side. The corresponding sensitivity and specificity for each probability cutoff are shown on the x- and y-axes. (A) shows the ROC curve from the delayed recall model including 10-word list delayed recall, age, and *APOE* genotype; (B) the MMSE model including MMSE orientation and memory, age, and *APOE* genotype; (C) the delayed recall model plus plasma Aβ~42~/Aβ~40~; and (D) the MMSE model plus plasma Aβ~42~/Aβ~40~. Abbreviations: Aβ, β-amyloid; MMSE, Mini--Mental State Examination; ROC, receiving operating characteristics.

4. Discussion {#sec4}
=============

In this study, we have developed four different amyloid risk models based on consecutively recruited nondemented patients in BioFINDER (n = 391). The models, which included the predictors age, *APOE* genotype, and parts of the MMSE or a delayed recall test, could accurately predict Aβ positivity (AUCs 0.81--0.83) and were validated in an independent population (ADNI, n = 170--661) with similar accuracies. The addition of plasma Aβ~42~/Aβ~40~ to *APOE*, age, and brief cognitive testing increased the accuracy slightly.

There are several previous suggestions on how to estimate Aβ positivity based on MRI measures, neuropsychological tests, *APOE* genotypes, and blood-based biomarkers [@bib8], [@bib9], [@bib12], [@bib38], [@bib39], [@bib40], [@bib41]. For example, we previously found that a combination of demographics, *APOE*, and longitudinal cognitive testing could be used to identify Aβ positivity in cognitively healthy controls [@bib12]. Recently, age and *APOE* were examined as predictors of Aβ positivity in MCI and subjects without objective cognitive decline [@bib42]. The AUCs in that study were lower (0.74--0.75), and no increase in AUC was seen when MMSE was added. This might be explained by how *APOE* was coded (only as ε4+/−) and that they used the total MMSE score, in contrast to the present study where we used four *APOE* groups based on their different contributing risks to Aβ accumulation [@bib19] and the use of only AD-specific parts of the MMSE score (orientation and memory) [@bib22], [@bib23].

A common limitation in many of the previous studies is that the Aβ prediction models have not been validated in an independent population. In the present models, we only used biomarkers or measures that previously have been shown to either be associated with Aβ deposition or to predict future development of AD dementia [@bib19], [@bib23], [@bib27], [@bib41], to reduce the risk of random inaccurate findings. The robustness of the models was confirmed by validating them in the independent ADNI population and in eight different subgroups ([Fig. 2](#fig2){ref-type="fig"}A--D). Note that the models performed well also in selected populations of individuals with only subjective cognitive symptoms (BioFINDER) and significant memory concerns or early MCI (ADNI), which may be of high interest in clinical trials of novel treatments. This also shows that the high accuracy of the models was not driven by the difference in cognitive status between subjective cognitive decline and MCI (BioFINDER) or early MCI and late MCI (ADNI).

The training (BioFINDER) and validation (ADNI) cohorts are different in many ways, which makes it more likely that the established models are indeed generalizable. The differences include, for example, geographic locations (Sweden and North America), education levels (lower in BioFINDER, high in ADNI), cognitive tests in different languages, and the patient selection process (consecutively recruited subjects referred to memory clinics in BioFINDER; selected enrollment in ADNI). Nonetheless, we want to mention potential limitations in these cohorts. The amyloidosis is to a large extent associated with late-onset AD, and the applicability in early-onset AD remains to be tested. The models need further validation in unselected primary care populations with individuals who seek medical care due to cognitive complaints (i.e., tested in populations with lower prevalence of Aβ positivity). Finally, the models should be validated in populations where the prevalence of different *APOE* genotypes differs from the North European/North American populations used in the present study [@bib43].

One popular aim has been to try to identify blood-based AD biomarkers. Plasma biomarker signatures of brain Aβ has, however, been difficult to replicate. Voyle et al. [@bib8] recently performed a large attempt to validated 35 different plasma proteins that had predicted Aβ positivity in previous studies [@bib38], [@bib39], [@bib40], [@bib44]. Unfortunately, none of the proteins were significantly associated with neocortical Aβ burden in the independent cohort. In the present study, we examined the additive effect of plasma Aβ~42~/Aβ~40~, NfL, and tau in our models because these biomarkers have been associated with AD [@bib27], [@bib28], [@bib29]. Although levels of NfL were significantly higher in Aβ-positive individuals ([Table 1](#tbl1){ref-type="table"}), only plasma Aβ~42~/Aβ~40~ was an independent predictor of brain Aβ in addition to age, *APOE* genotype, and cognitive testing. Plasma Aβ~42~/Aβ~40~ was also the predictor with the highest accuracy in the univariate analysis ([Fig. 1](#fig1){ref-type="fig"}B). It increased the AUC in both the delayed recall and MMSE models ([Fig. 1](#fig1){ref-type="fig"}A and [Supplementary Table 1](#appsec1){ref-type="sec"}) and increased the AUC when replicated in ADNI ([Fig. 2](#fig2){ref-type="fig"}C--D and [Supplementary Table 2](#appsec1){ref-type="sec"}). However, the clinical relevance of such a small increase in AUC is limited. Also, assay-dependent differences, or possibly preanalytical factors, may have contributed to different levels in the cohorts ([Table 1](#tbl1){ref-type="table"}). This highlights the need for an optimal unified analysis method for plasma Aβ~42~/Aβ~40~. Promising results with very high accuracies have been seen using mass spectrometry [@bib45], [@bib46], but unfortunately this is an advanced and time-consuming technique that cannot be implemented in primary care or large screening settings in the near future.

We propose that the presented models could be useful in mainly two settings, clinical AD trials and primary care. In clinical trials aimed at Aβ-positive subjects, amyloid risk models could reduce the number of unnecessary Aβ PET scans or LPs. In [Fig. 4](#fig4){ref-type="fig"}, we illustrate such a scenario using the delayed recall model. Here, we assume that 1000 Aβ-positive subjects are to be included in a clinical trial where Aβ PET is used to verify and assess the Aβ burden. An amyloid risk screening process in a population similar to the BioFINDER cohort could reduce the number of unnecessary (negative) Aβ PET scans by ∼90% and reduce the costs by \>3.5 million USD [@bib12], [@bib47], when using a probability cutoff of \>80% for undergoing an Aβ PET scan. In the trial scenario, the objective is thus to increase Aβ prevalence of the eligible population (high specificity). On the other hand, in a primary care workup of cognitive impairment or in a scenario where anti-Aβ drugs have become available, a high sensitivity may be preferred. Here, a probability threshold of around 30% would perhaps be more suitable to ensure a sensitivity of \>90% ([Fig. 3](#fig3){ref-type="fig"}). To facilitate such a use of the risk models, we have implemented them on <http://amyloidrisk.com> where age, *APOE* genotype, and cognitive test score can be entered to calculate the individual probability of being Aβ positive. The website is only intended for research and education until further validation has been conducted, but we believe it can be a useful tool for deciding who should undergo further evaluation with LP or Aβ PET to verify the presence of Aβ pathology.Research in Context1.Systematic review: We reviewed publications of β-amyloid (Aβ) prediction using PubMed. There are previous prediction models, but they lack adequate accuracy, replicable results, readily available measures, and/or individual risk stratification.2.Interpretation: Using just age, *APOE* genotype, and a brief cognitive test, we accurately predicted Aβ positivity in a training cohort (area under the receiver operating characteristics curve = 0.81--0.83, n = 391) and replicated the models in an independent validation cohort (area under the receiver operating characteristics curve = 0.80--0.82, n = 170--661). The individual probability of Aβ positivity can be calculated on [http://amyloidrisk.com](http://amyloidrisk.com/){#intref0045}. This is useful, for example, in the primary care workup of prodromal Alzheimer\'s disease or when screening participants in Alzheimer\'s disease trials for selecting persons who should be further examined with amyloid PET or cerebrospinal fluid analysis.3.Future directions: The models need to be replicated in populations with lower prevalence of Aβ positivity (e.g., primary care). The addition of plasma Aβ~42~/Aβ~40~ seems to improve the models, but further standardization of assays and preanalytical protocols is needed.Fig. 4Cost analysis for clinical trials. In this scenario, we assumed the same prevalence of Aβ positivity as in the BioFINDER study and a trial design that required 1000 Aβ+ subjects to be enrolled and Aβ status verified using Aβ PET (with an approximate cost of 4000 USD per PET scan [@bib12], [@bib47]). The y-axis shows the total Aβ PET cost, and the x-axis shows the probability of being Aβ positive according to the delayed recall model (this probability output is available on <http://amyloidrisk.com>). The line in the graph shows the study cost as a function of the Aβ probability, with the number needed to screen with the amyloid risk model on the left side (the prescreening process) and the number needed to undergo an Aβ PET scan to verify the Aβ status on the right side (normal trial screening process). The small costs for *APOE* genotyping (approximately 40 USD) and for administering the cognitive test were disregarded. The costs for verifying the Aβ status using LP and CSF Aβ42 analysis are approximately 10% of the costs for an Aβ PET scan (in Europe) [@bib47], [@bib48], so the costs on the y-axis can be divided by 10 for a CSF-based scenario. Abbreviations: Aβ, β-amyloid; APOE, apolipoprotein E; CSF, cerebrospinal fluid; LP, lumbar puncture; PET, positron emission tomography.
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Supplementary Fig. 1The estimates and intercepts of the amyloid risk models. All included variables were independently significant in the multivariable logistic regression analyses that predicted Aβ status. '10-word delayed recall' refers to the number of errors scored in the delayed recall part of the 10-wordlist from ADAS-cog. 'MMSE orientation and memory' refers the score from the orientation and three-word delayed recall parts of the MMSE. *APOE* estimates refers to the presence or absence (1 or 0) of each genotype.Supplementary Fig. 2Accuracy of *APOE* for predicting Aβ positivity. The figure shows the increase in AUC when stratifying *APOE* genotype into 2 groups (AUC 0.72, 95% CI 0.68--0.77), 3 groups (AUC 0.74, 95% CI 0.69--0.78), and 4 groups (0.75, 95% CI 0.71--0.80). The AUC is based on the probability output from a logistic regression analyses. A decrease of ≥2 in AIC indicates a significantly better model.Supplementary Fig. 3The estimates and intercepts of the SCD and MCI specific models. All included variables were independently significant in the multivariable logistic regression analyses that predicted Aβ status. '10\[HYPHEN\]word delayed recall' refers to the number of errors scored in the delayed recall part of the 10\[HYPHEN\]wordlist from ADAS\[HYPHEN\]cog. 'MMSE orientation and memory' refers the score from the orientation and three\[HYPHEN\]word delayed recall parts of the MMSE. *APOE* estimates refers to the presence or absence (1 or 0) of each genotype. Gender was coded as 0=male, 1=female.Supplementary Material
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[^1]: The data used in preparation of this article were obtained from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu){#intref0010}). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at <http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf>

[^2]: Abbreviations: Aβ, β-amyloid; ADNI, Alzheimer\'s Disease Neuroimaging Initiative; APOE, apolipoprotein E; ARWMC, age-related white matter changes; BioFINDER, Biomarkers For Identifying NeuroDegenerative Disorders Early and Reliably; EMCI, early MCI; LMCI, late MCI; MCI, mild cognitive impairment; MMSE, Mini--Mental State Examination; NfL, neurofilament light; SCD, subjective cognitive decline; SMC, significant memory concern, WML, white matter lesions.

[^3]: NOTE. Data are given in mean values (standard deviation) if not otherwise specified. All *P* values are Bonferroni corrected (multiplied by 6) to adjust for multiple comparisons. Within population comparisons (Aβ+ compared with Aβ*−*): ^a^*P* \< .05; ^b^*P* \< .01; ^c^*P* \< .001. Comparison between ADNI and BioFINDER: ^d^*P* \< .05; ^e^*P* \< .01; ^f^*P* \< .001. Comparison between total and plasma populations in ADNI: ^g^*P* \< .05; ^h^*P* \< .01; ^i^*P* \< .001.

[^4]: 11 cognitively normal participants had progressed to MCI at the present study baseline, and these were approximated as EMCI.
